source
- Israeli biotech's inhaled exosome therapy cuts respiratory failure and mortality in ARDS phase 2b trialNano24, an Israeli biotech company, tested its inhaled exosome product EXO‑CD24 in a mid‑stage study involving 90 patients with acute respiratory distress syndrome. The trial compared the therapy,…
- Gilead’s oral ulcerative colitis drug shows significant remission in Phase 2 trialGilead Sciences reported results from a Phase 2 trial of its oral ulcerative colitis drug emvistegrast. In the study, patients took a 200 mg daily dose for 12 weeks and achieved a 23% placebo-adju…